EFFECTS OF COMBINATION TREATMENT OF INTRAVESICAL RESINIFERATOXIN INSTILLATION AND HYDRODISTENTION PATIENTS WITH REFRACTORY PAINFUL BLADDER SYNDROME/INTERSTITIAL CYSTITIS: A PILOT STUDY

Hypothesis / aims of study
Painful bladder syndrome/interstitial cystitis (PBS/IC) is a disabling disease of the urinary bladder, and its etiology and treatment are not yet established. Current medications used in the treatment of PBS/IC have shown limited efficacy. This prospective study investigated the efficacy of intravesical resiniferatoxin (RTX) in PBS/IC refractory to medical treatment.

Study design, materials and methods
Patients with proven PBS/IC refractory to traditional medical treatment were enrolled. By randomized trial, a total of 18 consecutive patients were divided into two groups: treatment with hydrodistention and intravesical RTX (group 1) or treatment with hydrodistension only (group 2). We assessed bladder pain by use of a visual analogue pain scale (VAS), the maximal urine flow rate (Qmax), post-void residual urine volume (PVR), and a voiding diary before and 3 months after treatment.

Results
The median age of the 18 patients was 55.8 ± 6.9 years, and the median duration of symptoms before diagnosis was 3.6 ± 1.6 years. Frequency, functional bladder capacity, and score on a 5-point pain scale were significantly improved at 1-months after treatment in both groups. But after 3 month, only pain scale decreased significantly in group 1.

Interpretation of results
Intravesical RTX instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale.

Concluding message
Intravesical RTX instillation plus hydrodistention was effective in relieving pain but was not effective in improving lower urinary tract symptoms. Further larger studies are need to clarify the efficacy of combination treatment of intravesical RTX instillation and hydrodistention.

References

Disclosures
Funding: This work was financially supported by the grant from the Industrial Source Technology Development Program (10033634) of the Ministry of Knowledge Economy(MKE) of Korea and the National Research Foundation of Korea(NRF) grant funded by the Korea government(MEST) (No.2011-0020128) Clinical Trial: Yes Public Registry: No RCT: Yes Subjects: HUMAN Ethics Committee: the Institutional Review Board of Korea University Hospital Helsinki: Yes Informed Consent: Yes